INGREZZA® (valbenazine) Third Quarter Net Product Sales of $376 Million
INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion
Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease Submitted to the U.S. Food and Drug Administration
https://finance.yahoo.com/news/neurocrine-biosciences-reports-third-quarter-113000163.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.